β受体阻滞剂与晚期前列腺癌的癌症特异性生存:VA队列研究
该研究基于美国退伍军人健康管理局数据库,纳入2000-2008年诊断的高危前列腺癌(PSA>20)并接受ADT≥6个月的39198例患者,分析β受体阻滞剂(尤其是美托洛尔)使用与总生存、前列腺癌特异性生存及骨骼相关事件的关系。结果发现使用任何β受体阻滞剂或美托洛尔均未改善上述结局,与近期一项较小临床研究结论相反。
要点
- 高危前列腺癌ADT患者中,β受体阻滞剂使用未改善总生存、癌症特异性生存或骨骼相关事件。
- 本研究结果与近期一项较小临床研究相反,提示β受体阻滞剂对晚期前列腺癌无癌症特异性获益。
核心结论
- 在高危前列腺癌接受ADT的患者中,美托洛尔使用与总生存、前列腺癌特异性生存或骨骼相关事件风险改善无关。
研究设计与样本
- 回顾性队列研究,基于美国退伍军人健康管理局数据库,纳入2000-2008年诊断的高危前列腺癌(PSA>20)且接受ADT≥6个月的患者共39198例。
主要发现
- 使用任何β受体阻滞剂与总生存、前列腺癌特异性生存或骨骼相关事件改善均无关。
临床怎么用
- 对于高危前列腺癌接受ADT的患者,不应以改善肿瘤结局为目的使用β受体阻滞剂或美托洛尔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To interrogate the National Veterans Health Administration (VA) database to determine if beta-blocker use at time of initiation of androgen therapy deprivation (ADT) would result in improved oncological outcomes in advanced prostate cancer (PCa). METHODS: All men diagnosed with high risk PCa (PSA >20) from 2000-2008 who were on ADT ≥ 6 months were identified. Patients receiving ADT concurrently with primary radiation therapy were excluded. Pharmacy data was interrogated for all beta-blockers, but then focused on the selective beta-1 blocker metoprolol. Cox proportional hazards ratios were calculated for overall survival (OS), PCa specific survival (CSS) and skeletal related events (SREs). RESULTS: In 39,198 patients with high risk PCa on ADT, use of any beta-blocker was not associated with improvement in OS, CSS, or SREs. Further analyses focusing on metoprolol found that 10,224 (31.9%) had used metoprolol while 21,834 had no beta-blocker use. Multivariable analysis with Inverse Propensity Score Weighting, adjusted for factors including PSA, Gleason score, and duration ADT, found that utilization of metoprolol was not associated with improvement in OS (hazard ratio [HR] 0.97, P = .19), CSS (HR 0.94, P = .23) or SREs (HR 0.98, P = .79). CONCLUSION: In this large cohort, metoprolol use in conjunction with ADT in high risk PCa was not associated with improvement in OS, CSS, or risk of SRE. In contrast to a recent smaller clinical study, our data strongly suggests no cancer specific benefit to beta-blocker use in advanced PCa.
引用
- Posielski NM, Richards KA, Liou JI, et al. Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients With Advanced Prostate Cancer: A Veterans Administration Cohort Study. Urology. 2021. PMID: 33587939. doi:10.1016/j.urology.2021.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。